Michael Grainger

Michael Grainger

Associate
Michael Grainger
London
+44 (0)20 7447 4297

Michael Grainger is an associate in Goodwin’s Technology and Life Sciences groups in London. Mike advises clients on a broad range of corporate matters, with a focus on transactions in the life sciences, healthcare, and technology sectors. He has particular experience advising on private equity and venture capital investments/exits, mergers and acquisitions, corporate finance, and re-organisations as well as general corporate matters.

Experience

Exits

  • M&A Transactions
    • Advising KaNDy Therapeutics on its sale to Bayer for $425 million upfront with up to $450 million in development milestone payments and triple digit millions in commercial milestones.  
    • Advising Enterprise Therapeutics Ltd on the demerger and subsequent acquisition of its TMEM16A potentiator portfolio by Roche for an upfront consideration of £75 million and significant potential milestone payments.
    • Scottish Equity Partners-backed Dotmatics Limited on its sale to Insightful Science, an Insight Partners portfolio company providing software to the global life sciences community.
    • Advising Symprove Holdings Limited and its shareholders, on the sale of 100% of its share capital, to bd-capital for a total initial consideration of approximately £40 million.
    • Arctos Medical AG and its shareholders on the sale of 100% of its share capital to Novartis
    • Ares on the provision of their financing package in support of Midlothian Capital Partners to acquire Park Leisure.*
    • The selling shareholders in Ziarco Group Limited in connection with the sale of the company to Novartis.*
    • Mid Europa Partners on the acquisition of the entire issued share capital of Profi Rom Food S.R.L from Enterprise Investors.*
      IPO

  • IPO

VC Transactions

  • Investor
    • Advising Y Combinator’s Continuity growth fund as lead investor on a Series F investment of £113 million ($144 million) into Monzo Bank Limited.
    • Advising Lakestar on its series A investments into Yapily Ltd and Uncapped Ltd.
    • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited.
    • Representing the lead investor LSP Health Economics Fund 2 (advised by Life Science Partners) on the $28 million series C equity financing round of Lumeon Limited.
    • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited.
    • InMotion Ventures (part of the Jaguar Land Rover group) — Advised on various transactions including its investments into Arc.

  • Company
    • Vaccitech Limited in its $168 million Series B financing.
    • Advising NodThera Limited on its $55 million Series B equity financing.
    • Advising Exscientia Limited (an AI-driven drug discovery company) on its $26 million series B equity financing round. The Investors were Celgene Corporation, GT Healthcare Capital Partners and Evotec AG.
    • Brytlyt Limited, a company that is developing and commercializing GPU-accelerated data processing technology, on its completion of a £3.2 million Series A funding round led by Amadeus V Technology Fund LP and Finch Capital Fund II Cooperatief U.A.
    • Bicycle Therapeutics Limited on its £40 million Series B equity financing round, led by Vertex Global Fund I alongside Cambridge Innovation Capital and Longwood Fund, with existing investors including Novartis Venture Fund, SR One, and SVLS also participating in the round.*

* Denotes experience prior to joining Goodwin.

Credentials

Education

Legal Practice Course2015

The University of Law London

Graduate Diploma in Law2014

BPP Law School

BAEnglish and Related Literature2009

University of York

Admissions

Bars

  • Solicitor of the Senior Courts of England and Wales